参考文献:1.Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.CrossRef PubMed 2.Witjes JA, Comperat E, Cowan NC, De Santis M, Gakis G, Lebret T, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014;65(4):778–92.CrossRef PubMed 3.Von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602–8.CrossRef PubMed 4.Shirodkar SP, Lokeshwar VB. Potential new urinary markers in the early detection of bladder cancer. Curr Opin Urol. 2009;19(5):488–93.PubMedCentral CrossRef PubMed 5.Garcia-Fernandez M, Kissel H, Brown S, Gorenc T, Schile AJ, Rafii S, et al. Sept4/arts is required for stem cell apoptosis and tumor suppression. Genes Dev. 2010;24(20):2282–93.PubMedCentral CrossRef PubMed 6.Debatin KM. Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother. 2004;53(3):153–9.CrossRef PubMed 7.Joshi R, Kamat JP, Mukherjee T. Free radical scavenging reactions and antioxidant activity of embelin: biochemical and pulse radiolytic studies. Chem Biol Interact. 2007;167(2):125–34.CrossRef PubMed 8.Chitra M, Devi CS, Sukumar E. Antibacterial activity of embelin. Fitoterapia. 2003;74(4):401–3.CrossRef PubMed 9.Yang T, Lan J, Huang Q, Chen X, Sun X, Liu X, et al. Embelin sensitizes acute myeloid leukemia cells to TRAIL through XIAP inhibition and NF-κB inactivation. Cell Biochem Biophys. 2015;71(1):291–7.CrossRef PubMed 10.Waerner T, Alacakaptan M, Tamir I, Oberauer R, Gal A, Brabletz T, et al. ILEI: a cytokine essential for EMT, tumor formation, and late events in metastasis in epithelial cells. Cancer Cell. 2006;10(3):227–39.CrossRef PubMed 11.Beug ST, LaCasse EC, Korneluk RG. Smac mimetics combined with innate immune stimuli create the perfect cytokine storm to kill tumor cells. Oncoimmunology. 2014;3:e28541.PubMedCentral CrossRef PubMed 12.Yabal M, Muller N, Adler H, Knies N, Gross CJ, Damgaard RB, et al. Xiap restricts tnf- and rip3-dependent cell death and inflammasome activation. Cell Rep. 2014;7(6):1796–808.CrossRef PubMed 13.Paschall AV, Zimmerman MA, Torres CM, Yang D, Chen MR, Li X, et al. Ceramide targets xiap and ciap1 to sensitize metastatic colon and breast cancer cells to apoptosis induction to suppress tumor progression. BMC Cancer. 2014;14:24.PubMedCentral CrossRef PubMed 14.Moreno-Martinez D, Nomdedeu M, Lara-Castillo MC, Etxabe A, Pratcorona M, Tesi N, et al. Xiap inhibitors induce differentiation and impair clonogenic capacity of acute myeloid leukemia stem cells. Oncotarget. 2014;5(12):4337–46.PubMedCentral CrossRef PubMed 15.Shi Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell. 2002;9(3):459–70.CrossRef PubMed 16.Li X, Huang T, Jiang G, Gong W, Qian H, Zou C. Synergistic apoptotic effect of crocin and cisplatin on osteosarcoma cells via caspase induced apoptosis. Toxicol Lett. 2013;221(3):197–204.CrossRef PubMed
作者单位:X. Fu (1) (2) X. Pang (1) H. Qi (1) S. Chen (1) Y. Li (1) W. Tan (1)
1. Department of Urology, Nanfang Hospital, Southern Medical University, No. 1838, North of Guangzhou Avenue, Baiyun District, Guangzhou, 510515, Guangdong Province, China 2. Department of Urology, Kaiping Central Hospital, Kaiping, 529300, China
刊物主题:Oncology;
出版者:Springer Milan
ISSN:1699-3055
文摘
Background Bladder cancer is the second most common urological malignancy around the world and is by far the most frequent urological malignancy in China. Embelin is an active compound identified as a novel X-chromosome-linked IAP (XIAP) inhibitor from the Embelia ribes that exhibits various medicinal effects including anti-inflammatory and anti-cancer activities. However, therapeutic effect of Embelin to human bladder cancer is not yet determined.